Status:
COMPLETED
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine safety \& efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo \& to evaluate quality of sleep, overall quality of life,...
Eligibility Criteria
Inclusion
- Documented clinical diagnosis according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) meeting criteria 296.2x Major Depressive Disorder,
- Single Episode, or 296.3x Major Depressive Disorder,
Exclusion
- Patients with a DSM-IV Axis I disorder other than MDD w/in 6 months of enrollment,
- Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patients current psychiatric status.
- Patients whose current episode of depression\>12 months or \<4 weeks from enrollment
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT00278941
Start Date
December 1 2005
End Date
August 1 2007
Last Update
March 25 2009
Active Locations (168)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Tuscaloosa, Alabama, United States
3
Research Site
Mesa, Arizona, United States
4
Research Site
Peoria, Arizona, United States